Interactions of hormones stimulating and inhibiting uterine contraction were studied in vitro in uteri from oophorectomized rats. The ,3-adrenergic effector, isoproterenol, a potent inhibitor of contraction, produced a dose-related increase of adenylate cyclase and accumulation of adenosine 3' :5'-cyclic monophosphate (cAMP) that was inhibitable by propranolol. Oxytocin, which stimulates contraction, effectively inhibited accumulation of uterine cAMP induced by isoproterenol in the presence or absence of theophylline. Prostaglandins E2 and F2a, each at a maximum effective concentration of 0.5 AMM, also inhibited accumulation of cAMP induced by isoproterenol, consistent with their effect in stimulation of uterine contraction. Prostaglandin E2, but not prostaglandin F2a, stimulated cAMP accumulation in a dose-related manner at concentrations in excess of 0.5 MM. Neither propranolol nor oxytocin inhibited that response. Bovine endometrial adenylate cyclase failed to respond to isoproterenol but was stimulated by prostaglandins El and E2. When myometrial preparations were studied, isoproterenol stimulation and prostaglandin effects were observed as for whole castrate uterus. The competitive physiological actions of ,B-adrenergic effectors on the one hand, and oxytocin and prostaglandins on the other hand, are based on their influences on a myometrial adenylate cyclase. Stimulation of uterine cAMP accumulation by prostaglandin Ea is due to action at a different and unrelated site.
Uterine tissue is designed to respond specifically to hormonal influences in order to provide the appropriate environment for implantation, fetal growth and development, and parturition. It appears to be ideal for study of the relationship between steroid-mediated and cAMP-mediated responses. Recently, it was shown that smooth muscle, particularly uterus, has an adenylate cyclase system whose activation by ,B-adrenergic effectors resulted in inhibition of contractility (1) (2) (3) (4) . It was further demonstrated that contractions produced by oxytocin, acetylcholine, and calcium were inhibited by fl-adrenergic effectors, theophylline, and dibutyryl-cAMP (3, 4) in association with an increase in adenylate cyclase activity (5) (6) (7) . Prostaglandins, particularly those of the E series, are potent stimulators of uterine contraction despite the fact that they stimulate uterine adenylate cyclase activity (7, 8) .
In these studies, we show that the stimulatory effects of oxytocin and prostaglandins E2 and F2a on castrate uterus and myometrium may well be due to inhibition of cAMP accumulation due to f3-adrenergic activity.
MATERIALS AND METHODS
[3H]cAMP (16. was time-and dose-related and that was inhibited by propranolol ( Fig. 1 ). Half-maximal stimulation was usually obtained at a concentration of about 5 MAM with a plateau of peak action at from 5-15 min of incubation.
Oxytocin had no effect on baseline concentration of uterine cAMP in the presence or absence of theophylline. As shown in Table 1 (12) . Values expressed in terms of the activity of controls are means +4-SEM, based on four experiments. (a) 10 mU of oxytocin/ml; (b) 5 mU of oxytocin/ml; (c) 10 ,uM isoproterenol; (d) 10 MuM isoproterenol + 10 mU of oxytocin/ml; (e) 10MiM isoproterenol + 1 mU of oxytocin/ml; (f) 0.13 M NaF. Incubation conditions were the same as in Fig. 1 . The duration of treatment with oxytocin was 10 min followed by 5 min with oxytocin + isoproterenol(10 MM). In Exp, 3B, the order of incubation was reversed. Values are means of four determinations ASEM. * P < 0.01; t P < 0.05; -, not done.
traction of the uterus and in demonstrating competition with j3-adrenergic effectors (4, 7). However, in the only other report where specific measurements have been made (13), a significant inhibition was not found. This may have been due to differences in experimental conditions, since in that report estrogen-stimulated uteri were exposed to oxytocin for a very brief period.
Prostaglandins (PG) of the E and F series have been known to stimulate uterine contraction in vivo (8) . In the one available report of in vitro studies, PG E1 and E2 caused an increase in uterine adenylate cyclase activity, while PGF2a was inactive (7) .
The effects of PGF2,a and PGE2 on uterine cAMP concentration are shown in Fig. 3 , which is a composite of four experiments. In each experiment, the amount of cAMP produced by treatment with isoproterenol alone is represented as 100%. PGF2a failed to induce an increase in the amount of uterine cAMP, but PGE2 was quite active, with a significant increment noted at a concentration of 0.5 MuM. However, both PGE2 and PGF2a were potent inhibitors of isoproterenol stimulation of uterine cAMP with a maximal inhibition achieved at a concentration of 0.5 uM each. At each dose in excess of 0.5 ,uM, isoproterenol augmented the expected stimulation of cAMP accumulation due to PGE2. When increasing concentrations of isoproterenol were tested for the effect on uterine cAMP accumulation in the presence or absence of 2 ,uM PGE2, inhibition was first noted when a potent stimulatory concentration of isoproterenol was used, suggesting a relation between the PGE2 inhibitory site and the ,3-adrenergic receptor. These results are consistent with those of Marumo and Edelman (14) and of Shaw et al. (15) , indicating that the inhibition of hormone effects produced by prostaglandins was associated with a decrease of tissue cAMP.
Since we were relating hormone action to known effects on myometrial contractivity, it was necessary to verify that the hormone-induced alterations of cAMP concentration were not occurring principally in the endometrium. As shown in Table 2 , bovine endometrial strips failed to respond to isoproterenol but had a vigorous response to PGE1 and PGE2. Myometrial strips prepared from oophorectomized rats by scraping away the erfdometrium behaved exactly as did whole castrate uterus (Fig. 4) . Isoproterenol induced cAMP accumulation, while both PGE2 and PGF2at were inhibitory. It was of interest that PGF2a appeared to be a more potent inhibitor in the myometrial preparation.
The data best fit the hypothesis that prostaglandins E2 and F2a interfere with the ,3-adrenergic response in myometrium to inhibit cAMP formation and stimulate uterine contraction, while PGE2 also stimulates other adenylate cyclases. In further support, it was found ( Table 3) influence on PGE2-induced accumulation of cAMIP. When the inhibitory effect of propranolol was tested (Fig. 5 maximal. However, much higher prostaglandin concentrations were necessary to stimulate cAMP maximally. A similar picture has emerged from studies of lipolysis regulated by hormones in epididymal fat pads where, in addition, a physical separation of the stimulatory and inhibitory adenylate-eyclase sites was possible (16, 17) .
While both endometrium and myometrium contain adenylate cyclases that can be stimulated by PGE, the f3-adrenergic responsive cyclase is limited to the myometrium (Table 2 , Fig. 4) , indicating at least a partial physical separation.
The influences of catecholamines, oxytocin, and certain prostaglandins on myometrial contractility are well known. Studies with dibutyryl cAMP and phosphodiesterase inhibitors have demonstrated an inhibition of contractility (4) . Recently, it has been reported that acetylcholine, a myometrial stimulator, significantly inhibited epinephrineinduced accumulation of cAMP (6) . Those reports, in concert with the current data, have shown that the principal hormones affecting myometrial contractility interact in such a way as to alter myometrial cAMP concentration in a manner consistent with their physiological role. Added weight is therefore given to the theory that cAMP is the intracellular messanger that transduces the net hormonal influence in smooth muscle. Direct measurements in these laboratories have also shown that the increase in cAMP produced by isoproterenol results in activation of a myometrial protein kinase whose functions remain to be clarified.
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